Makker, V. et al. Endometrial most cancers. Nat. Rev. Dis. Primers 7, 88. https://doi.org/10.1038/s41572-021-00324-8 (2021).
Siegel, R. L., Miller, Okay. D., Fuchs, H. E. & Jemal, A. Most cancers statistics, 2022. CA Most cancers J. Clin. 72, 7–33. https://doi.org/10.3322/caac.21708 (2022).
Calle, E. E., Rodriguez, C., Walker-Thurmond, Okay. & Thun, M. J. Obese, weight problems, and mortality from most cancers in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348, 1625–1638. https://doi.org/10.1056/NEJMoa021423 (2003).
Nationwide Most cancers Institute Surveillance, Epidemiology, and Finish outcomes program. Most cancers Stat info: Uterine Most cancers. https://seer.most cancers.gov/statfacts/html/corp.html (2021). Accessed 1 Aug 2021.
Bokhman, J. V. Two pathogenetic forms of endometrial carcinoma. Gynecol. Oncol. 15, 10–17. https://doi.org/10.1016/0090-8258(83)90111-7 (1983).
Masood, M. & Singh, N. Endometrial carcinoma: Modifications to classification (WHO 2020). Diagn. Histopathol. 27, 493–499. https://doi.org/10.1016/j.mpdhp.2021.09.003 (2021).
Kandoth, C. et al. Built-in genomic characterization of endometrial carcinoma. Nature 497, 67–73. https://doi.org/10.1038/nature12113 (2013).
Mohr, A. M. & Mott, J. L. Overview of microRNA biology. Semin. Liver Dis. 35, 3–11. https://doi.org/10.1055/s-0034-1397344 (2015).
Ali Syeda, Z., Langden, S. S. S., Munkhzul, C., Lee, M. & Track, S. J. Regulatory mechanism of microRNA expression in most cancers. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21051723 (2020).
Peng, Y. & Croce, C. M. The position of MicroRNAs in human most cancers. Sign Transduct. Goal. Ther. 1, 15004. https://doi.org/10.1038/sigtrans.2015.4 (2016).
Gebert, L. F. R. & MacRae, I. J. Regulation of microRNA operate in animals. Nat. Rev. Mol. Cell Biol. 20, 21–37. https://doi.org/10.1038/s41580-018-0045-7 (2019).
Grzywa, T. M., Klicka, Okay. & Włodarski, P. Okay. Regulators at each step-how microRNAs drive tumor cell invasiveness and metastasis. Cancers (Basel) https://doi.org/10.3390/cancers12123709 (2020).
Hanahan, D. Hallmarks of most cancers: New dimensions. Most cancers Discov. 12, 31–46. https://doi.org/10.1158/2159-8290.Cd-21-1059 (2022).
Ruan, Okay., Fang, X. & Ouyang, G. MicroRNAs: Novel regulators within the hallmarks of human most cancers. Most cancers Lett. 285, 116–126. https://doi.org/10.1016/j.canlet.2009.04.031 (2009).
Zhang, B., Pan, X., Cobb, G. P. & Anderson, T. A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302, 1–12. https://doi.org/10.1016/j.ydbio.2006.08.028 (2007).
Klicka, Okay., Grzywa, T. M., Klinke, A., Mielniczuk, A. & Włodarski, P. Okay. The position of miRNAs within the regulation of endometrial most cancers invasiveness and metastasis—a scientific overview. Cancers (Basel) https://doi.org/10.3390/cancers13143393 (2021).
Donkers, H., Bekkers, R. & Galaal, Okay. Diagnostic worth of microRNA panel in endometrial most cancers: A scientific overview. Oncotarget 11, 2010–2023. https://doi.org/10.18632/oncotarget.27601 (2020).
Banno, Okay. et al. MicroRNAs in endometrial most cancers. Int. J. Clin. Oncol. 18, 186–192. https://doi.org/10.1007/s10147-013-0526-9 (2013).
Kontomanolis, E. N. & Koukourakis, M. I. MicroRNA: The potential regulator of endometrial carcinogenesis. Microrna 4, 18–25. https://doi.org/10.2174/2211536604666150710094418 (2015).
Sarver, A. L., Sarver, A. E., Yuan, C. & Subramanian, S. O. M. C. D. OncomiR most cancers database. BMC Most cancers 18, 1223. https://doi.org/10.1186/s12885-018-5085-z (2018).
Anaya, J. OncoLnc: Linking TCGA survival information to mRNAs, miRNAs, and lncRNAs. PeerJ Comput. Sci. 2, e67 (2016).
Li, J. H., Liu, S., Zhou, H., Qu, L. H. & Yang, J. H. starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interplay networks from large-scale CLIP-Seq information. Nucleic Acids Res. 42, D92–D97. https://doi.org/10.1093/nar/gkt1248 (2014).
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).
Kanehisa, M. Towards understanding the origin and evolution of mobile organisms. Protein Sci. 28, 1947–1951. https://doi.org/10.1002/professional.3715 (2019).
Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: Integrating viruses and mobile organisms. Nucleic Acids Res. 49, D545–D551. https://doi.org/10.1093/nar/gkaa970 (2021).
Zaheer, U. et al. Expression profile of MicroRNA: An rising hallmark of most cancers. Curr. Pharm. Des. 25, 642–653. https://doi.org/10.2174/1386207322666190325122821 (2019).
Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838. https://doi.org/10.1038/nature03702 (2005).
Petrovic, N., Ergün, S. & Isenovic, E. R. Ranges of microRNA heterogeneity in most cancers biology. Mol. Diagn. Ther. 21, 511–523. https://doi.org/10.1007/s40291-017-0285-9 (2017).
Guo, Y. X. et al. The position of miR-23b in most cancers and autoimmune illness. J. Oncol. 2021, 6473038. https://doi.org/10.1155/2021/6473038 (2021).
Chen, S. et al. The position of metastasis-associated in colon most cancers 1 (MACC1) in endometrial carcinoma tumorigenesis and development. Mol. Carcinog. 56, 1361–1371. https://doi.org/10.1002/mc.22599 (2017).
Jayaraman, M. et al. Identification of novel diagnostic and prognostic miRNA signatures in endometrial most cancers. Genes Most cancers 8, 566–576. https://doi.org/10.18632/genesandcancer.144 (2017).
Kalinkova, L. et al. Discriminating miRNA profiles between endometrioid well- and poorly-differentiated tumours and endometrioid and serous subtypes of endometrial cancers. Int. J. Mol. Sci. 21, 1. https://doi.org/10.3390/ijms21176071 (2020).
Shang, C., Lu, Y. M. & Meng, L. R. MicroRNA-125b down-regulation mediates endometrial most cancers invasion by focusing on ERBB2. Med. Sci. Monit. 18, Br149-155. https://doi.org/10.12659/msm.882617 (2012).
Buchynska, L. G., Borykun, T. V., Iurchenko, N. P., Nespryadko, S. V. & Nesina, I. P. Expression of microRNA in tumor cells of endmetrioid carcinoma of endometrium. Exp. Oncol. 42, 289–294. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-4.15522 (2020).
Wu, D., Huang, H.-J., He, C.-N. & Wang, Okay.-Y. MicroRNA-199a-3p regulates endometrial most cancers cell proliferation by focusing on mammalian goal of rapamycin (mTOR). Int. J. Gynecol. Most cancers 23, 1191–1197. https://doi.org/10.1097/IGC.0b013e31829ea779 (2013).
Cohn, D. E. et al. Complete miRNA profiling of surgically staged endometrial most cancers. Am. J. Obstet. Gynecol. 202(656), e651-656.e658. https://doi.org/10.1016/j.ajog.2010.02.051 (2010).
Cohn, D. E. et al. Complete miRNA profiling of surgically staged endometrial most cancers. Am J Obstet Gynecol 202(656), e651-658. https://doi.org/10.1016/j.ajog.2010.02.051 (2010).
Track, J. et al. Potential worth of miR-221/222 as diagnostic, prognostic, and therapeutic biomarkers for ailments. Entrance. Immunol. https://doi.org/10.3389/fimmu.2017.00056 (2017).
Bai, H. & Wu, S. miR-451: A novel biomarker and potential therapeutic goal for most cancers. Onco Targets Ther. 12, 11069–11082. https://doi.org/10.2147/OTT.S230963 (2019).
Notaro, S. et al. Evaluating L1CAM expression in human endometrial most cancers utilizing qRT-PCR. Oncotarget 7, 40221–40232. https://doi.org/10.18632/oncotarget.9574 (2016).
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B. & Watari, H. miR-34a, miR-424 and miR-513 inhibit MMSET expression to repress endometrial most cancers cell invasion and sphere formation. Oncotarget 9, 23253–23263. https://doi.org/10.18632/oncotarget.25298 (2018).
Wang, Z. et al. MicroRNA-34a inhibits cells proliferation and invasion by downregulating Notch1 in endometrial most cancers. Oncotarget 8, 111258–111270. https://doi.org/10.18632/oncotarget.22770 (2017).
Schirmer, U. et al. Function of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget 5, 462–472. https://doi.org/10.18632/oncotarget.1552 (2014).
Nakamura, N., Davis, Okay., Yan, J., Sloper, D. T. & Chen, T. Elevated estrogen ranges altered microRNA expression in prostate and plasma of rats dosed with intercourse hormones. Andrology 8, 1360–1374. https://doi.org/10.1111/andr.12780 (2020).
He, B. et al. miRNA-based biomarkers, therapies, and resistance in Most cancers. Int. J. Biol. Sci. 16, 2628–2647. https://doi.org/10.7150/ijbs.47203 (2020).
Coll-de la Rubia, E. et al. Prognostic biomarkers in endometrial most cancers: A scientific overview and meta-analysis. J. Clin. Med. 9, 1. https://doi.org/10.3390/jcm9061900 (2020).
Hutt, S. et al. The position of biomarkers in endometrial most cancers and hyperplasia: A literature overview. Acta Oncol. (Stockholm, Sweden) 58, 342–352. https://doi.org/10.1080/0284186x.2018.1540886 (2019).
Klopfleisch, R., Weiss, A. T. & Gruber, A. D. Excavation of a buried treasure–DNA, mRNA, miRNA and protein evaluation in formalin mounted, paraffin embedded tissues. Histol. Histopathol. 26, 797–810. https://doi.org/10.14670/hh-26.797 (2011).
Grzywa, T. M. et al. Larger mutation burden in excessive proliferation compartments of heterogeneous melanoma tumors. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22083886 (2021).
Grzywa, T. M. et al. miR-410-3p is induced by vemurafenib through ER stress and contributes to resistance to BRAF inhibitor in melanoma. PLoS ONE 15, e0234707. https://doi.org/10.1371/journal.pone.0234707 (2020).
Pełka, Okay. et al. miR-96-5p, miR-134-5p, miR-181b-5p and miR-200b-3p heterogenous expression in websites of prostate most cancers versus benign prostate hyperplasia-archival samples examine. Histochem. Cell Biol. 155, 423–433. https://doi.org/10.1007/s00418-020-01941-2 (2021).
Grzywa, T. M. et al. Lineage-dependent position of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas through MAPK, PTEN/AKT, and STAT3 signaling pathways. Endocrine 65, 646–655. https://doi.org/10.1007/s12020-019-01960-7 (2019).
Guzmán, C., Bagga, M., Kaur, A., Westermarck, J. & Abankwa, D. ColonyArea: An ImageJ plugin to routinely quantify colony formation in clonogenic assays. PLoS ONE 9, e92444. https://doi.org/10.1371/journal.pone.0092444 (2014).
